Acurx Pharmaceuticals, Inc. — Form S-1
Filed September 8, 2026 · analyzed by the Registration Agent
S-1
— Neutral
significance 28/100
What the filing says
Acurx entered a purchase agreement with Lincoln Park Capital Fund, LLC on May 8, 2025, committing Lincoln Park to purchase up to $12.0 million of common stock over 24 months. As of September 8, 2026, $9.2 million has been drawn (3,135,000 shares sold). This S-1 registers 1,500,000 additional shares for resale by Lincoln Park, representing the remaining ~$2.8 million available under the agreement. The company receives proceeds only when it chooses to sell; Lincoln Park may resell at any time.
Why this rating
Routine equity financing registration. At $13.7M market cap, $2.8M remaining commitment is ~20% of company size—material but not transformational. Already $9.2M drawn; this is incremental. Dilution risk disclosed but controlled by company (timing/amount at its discretion). No business/operational change.
See more from September 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.